Quick Answer
Xeris Biopharma Holdings, Inc. reported Long-Term Debt of $220.34 million for fiscal year 2025.
Xeris Biopharma Holdings, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $220.34M | +1.5% |
| 2024 | $217.01M | +13.7% |
| 2023 | $190.93M | +2.1% |
| 2022 | $187.07M | +112.4% |
| 2021 | $88.07M | +1.2% |
| 2020 | $87.02M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $219.47M | +1.5% | +0.4% |
| June 30, 2025 | $218.63M | -5.1% | +0.4% |
| March 31, 2025 | $217.81M | -5.2% | +0.4% |
| December 31, 2024 | $217.01M | +13.7% | +0.4% |
| September 30, 2024 | $216.23M | +13.6% | -6.2% |
| June 30, 2024 | $230.48M | +22.5% | +0.4% |
| March 31, 2024 | $229.67M | +22.4% | +20.3% |
| December 31, 2023 | $190.93M | +2.1% | +0.3% |
- Xeris Biopharma Holdings, Inc. showed an increase of +1.5% in Long-Term Debt compared to the prior fiscal year.
- Over the 2020–2025 period, Xeris Biopharma Holdings, Inc.’s long-term debt has grown by 153.2% (from $87.02 million to $220.34 million).
- The most recent figure is from Xeris Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: